Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 377Myelodysplastic Syndromes 159Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 32Myeloproliferative Disorders 23Hematologic Neoplasms 20Neoplasms 19Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, T-Cell, Peripheral 13Primary Myelofibrosis 12Neoplasm, Residual 12Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Leukemia, Myelomonocytic, Acute 10Hodgkin Disease 10Myelodysplastic-Myeloproliferative Diseases 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8Breast Neoplasms 8

Interventions

Pemetrexed 39Cisplatin 33pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Imatinib Mesylate 3Cerebral Decortication 3tislelizumab 2sargramostim 2fludarabine phosphate 2defactinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mesothelioma × Azacitidine × Clear all
NCT00629343 2025-06-05

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Columbia University

Phase 1 Completed
27 enrolled 7 charts
Other solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡